United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.34, $0.79 better than the analyst estimate of $2.55. Revenue for the quarter came in at $381.4 million versus the consensus estimate of $355.83 million.

"2018 was a truly transformative year for United Therapeutics. We signed four major agreements to acquire new product candidates, including an in-licensing agreement for ralinepag, representing our largest deal to date," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "At the same time, we continued to execute against our existing commercial and clinical goals, including the successful readout of our FREEDOM-EV clinical trial, significant progress toward near-term phase III readouts for our BEAT and DISTINCT studies, and an increase to a record number of patients being treated with our treprostinil therapies."

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.